SMi are pleased to announce the launch of  the Respiratory  Drug Delivery  conference as part of the newly branded Asthma and COPD series, which will be held in London on the 5th-6th December 2019.

With the rising prevalence of respiratory diseases such as Asthma, cystic fibrosis and COPD, this group of diseases are now amongst the leading cause death, affecting over 500 million adults and children worldwide. Lung cancer now accounts for over 50% of all respiratory disease related deaths in Europe, yet little work is being done to reduce this high mortality rate.

Opportunities for drug development has effectively resulted in the global pulmonary and respiratory drug delivery market expecting to reach 64 billion USD (6.7% CAGR) by 2025. However, the unmet medical needs of respiratory disease sufferers remain.

Join us this year as SMi aim to bring together clinical researchers, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments that adhere to patient’s needs, analyzing the success of digital medical devices and connective health technology in aiding the diagnosis of severe asthma and COPD. This year will also investigate the developing issues surrounding pulmonary and nasal combination product design.